Immutep S.A.S.
eftilagimod alfa
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for eftilagimod alfa in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06726265: Phase 3 trial, sponsor Immutep S.A.S., drug eftilagimod alfa. Primary completion date 2027-06 (estimated).”